Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
نویسندگان
چکیده
منابع مشابه
OnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse
Chronic Migraine (CM) is one of the most disabling primary headache disorders affecting 2% of general population. CM is defined as headaches on >15 days per month for >3 months of which >8 days fulfill the criteria for migraine with or without aura or relieved by migrainespecific treatment [1].CM has an important economic and social impact compared with episodic migraine [2]. CM patients requir...
متن کاملIncobotulinumtoxinA (Xeomin®) and OnabotulinumtoxinA (Botox®) for Chronic Migraine Headache: Experience with Higher Doses and Changes to the Injection Technique
Background: OnabotulinumtoxinA has proven efficacious as a preventive treatment in patients with chronic migraine. However, non-response and tolerability problems were reported for some patients. This open-label study investigated long-term treatment with incobotulinumtoxinA in chronic migraine patients who were non-responsive to onabotulinumtoxinA injections. Methods: Patients received pericra...
متن کاملOnabotulinumtoxinA for the treatment of chronic migraine.
Chronic migraine is a common primary headache disorder that actively afflicts as many as 1 in 50 individuals and accounts for a disproportionate share of the financial cost, pain, and emotional suffering produced by migraine generally. “Chronic migraine” implies that one has an established history of migraine, has been experiencing headaches on at least 15 days of each month for at least 3 cons...
متن کاملProlonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
Dear Editor, OnabotulinumtoxinA (BOTOX) has been approved for prophylaxis in chronic migraine (CM) since 20101 based on the findings of the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) trial.2 The duration of BOTOX efficacy is known to be 3 months, but prolonged efficacy (>3 months) after a single cycle of BOTOX has not been evaluated thoroughly. Moreover, the efficacy and...
متن کاملA review of onabotulinumtoxinA (Botox).
OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Headache and Pain
سال: 2011
ISSN: 1129-2369,1129-2377
DOI: 10.1007/s10194-011-0294-8